Coeptis Therapeutics (NASDAQ:COEP) Stock Price Up 12.2% - What's Next?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report) shares rose 12.2% on Tuesday . The stock traded as high as $17.13 and last traded at $17.00. Approximately 77,154 shares changed hands during mid-day trading, an increase of 92% from the average daily volume of 40,114 shares. The stock had previously closed at $15.15.Get Coeptis Therapeutics alerts:Analyst Upgrades and DowngradesSeparately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Coeptis Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Coeptis Therapeutics presently has a consensus rating of "Sell".Read Our Latest Stock Report on Coeptis TherapeuticsCoeptis Therapeutics Trading Up 12.2%The stock has a market cap of $90.78 million, a P/E ratio of -5.18 and a beta of -0.50. The firm's 50 day simple moving average is $15.16 and its two-hundred day simple moving average is $11.96. The company has a quick ratio of 0.83, a current ratio of 2.21 and a debt-to-equity ratio of 0.01. Institutional Investors Weigh In On Coeptis TherapeuticsA hedge fund recently bought a new stake in Coeptis Therapeutics stock. Yorkville Advisors Global LP bought a new stake in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 8,000 shares of the company's stock, valued at approximately $140,000. Coeptis Therapeutics accounts for about 0.0% of Yorkville Advisors Global LP's portfolio, making the stock its 24th largest holding. Yorkville Advisors Global LP owned 0.17% of Coeptis Therapeutics as of its most recent SEC filing. Institutional investors own 13.88% of the company's stock. About Coeptis Therapeutics (Get Free Report)Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.See AlsoFive stocks we like better than Coeptis TherapeuticsAre Penny Stocks a Good Fit for Your Portfolio?What’s on the Thanksgiving Table? A Stock Pick for Every CourseWhat Are the FAANG Stocks and Are They Good Investments?Why Home Depot’s Pain Could Be a Long-Term Investor’s GainDividend Screener: How to Evaluate Dividend Stocks Before BuyingQualcomm’s Bulls Are Running Out of Room to Be WrongThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Coeptis Therapeutics Right Now?Before you consider Coeptis Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coeptis Therapeutics wasn't on the list.While Coeptis Therapeutics currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here